Sumitomo Chemical India Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0u5m34qv1shj2503ti3o7vsy.pdf

Key Takeaways


The Quarter's Damage: Weather, Inventory & Price

Chetan Shah: "we experienced an unbelievable dry spell in the month of August, which ruined the entire planning and entire agrochemical consumption."

Margin Mechanics: The Hit and the Recovery

Chetan Shah: "We continue to be confident about this kind of profitability levels in the medium to long term. But in the current year, because of challenging environment and situation, we have taken a little bit of a hit."

New Product Engine: Launches, Feedback & Ramp-Up

Chetan Shah: "we are very, very confident about these products. And I mean just to give you an example. We had a recent meeting down South, and the feedback that we received from the distributors and the farmers was overwhelming on this new introduction."

Capex Projects: Bhavnagar, Tarapur & Dahej


Barrix Acquisition & Inorganic Strategy

Kunal Mittal: "So, I think we are looking at opportunities, I think, as we have mentioned this Barrix that we've announced. So, our preference will be for smaller and niche segments instead of acquiring a very, very large company and at a very, very high valuation."

Demand Outlook: Cautious Optimism for H2, Real Normalcy in FY25

Chetan Shah: "I would say that cautiously if one wants to approach this subject, I think up to Q4 we may see better prospect than the Q1 and Q2. But a real normalcy should come by the first quarter of '24-'25."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin recoveryTarget around 19-20%FY25
Five-molecule capex utilization80% to 100% of potential (INR200-220 crores peak)FY25
Bhavnagar & Tarapur ramp-upMajor revenue contributionFY25
Dahej environmental clearanceApproval expectedFY24
Dahej capexINR300 croresNext two to three years
Export volume normalizationReturn to FY22-23 volumesNext financial year
Domestic growth normalizationNormal consumption season, stable prices, new products contributeFY25
Promalin next seasonSales from Q4 onwardsQ4 FY24
Glyphosate government hearingCompany and industry objecting to proposalDecember 7

Key Metrics

MetricQ2 FY24
Revenue₹903 cr, compared to ₹1,121 cr in Q2 FY23
Gross margin38.4%, compared to 31.1% in Q1 FY24, sequential improvement
EBITDA₹188 cr, compared to ₹278 cr in Q2 FY23
EBITDA margin20.8%, compared to 24.8% in Q2 FY23
Profit after tax₹143 cr, compared to ₹201 cr in Q2 FY23
PAT margin15.9%, compared to 18% in Q2 FY23
H1 FY24 revenue₹1,628 cr, compared to ₹2,106 cr in H1 FY23
H1 FY24 domestic revenue share89% of overall revenues, export contributing the rest
H1 FY24 insecticides share40% of total revenue
H1 FY24 export revenue share11%, down from approximately 19% in H1 FY23
H1 FY24 EBITDA₹269 cr, compared to ₹466 cr in H1 FY23
H1 FY24 EBITDA margin16.5%, compared to 22.1% in H1 FY23
H1 FY24 profit after tax₹205 cr, compared to ₹340 cr in H1 FY23
Net working capital cycle70 days, reduction of 24 days as on September 2023 compared to June 2023 and September 2022
H1 FY24 collections₹2,000 cr against sales of ₹1,628 cr
Domestic business degrowth in Q2~10% compared to Q2 FY23
Domestic volume decline in H1~12% (per an analyst's math), with ~3% attributed to price out of ~15% total domestic decline
Export decline in H145% to 50% total decline, roughly 20% from price and 25% to 30% from volumes
Glyphosate volume growth in H15% increase, prices dropped 25% to 30%
Specialty product portfolio value decline3% lower prices compared to FY23
Animal Nutrition volume growth in H131% increase, prices down 38% YoY
High-cost inventory profit margin impact12% to 15% lost in Q1, declining to ~1.5% by end of September
Farmers reached0.44 crore-plus farmers and 40,000 dealers
Distribution network15,000 direct distributors and 60 depots
Portfolio brands200-plus agrochemical brands, including 20-plus mega brands
New products launched in H16 products: three herbicides, one insecticide, two fungicides
Capex guidance15% of EBITDA normalized capex for next year
Dahej initial capex₹300 cr over next two to three years
Pheromone segment market size₹400 cr to ₹500 cr currently, expected to double or triple in four to five years